Introduction
Epilepsy, seizures and status epilepticus (SE) impose a considerable burden on the affected person and society in general. 1 SE itself is a life-threatening condition and a medical emergency with different clinical definitions. 2 Traditionally, SE was defined as a single clinical seizure lasting more than 30 min, or as repeated seizures over a period of more than 30 min without intervening recovery of consciousness. 2, 3 The operational definition was recently modified for practical reasons of urgent treatment initiation: persistent seizure activity for 5 min or more should be therefore considered as SE and should be treated accordingly. 2 Incidence is estimated at about 20/100,000 applying the traditional definition and the mortality rate lies between 3 and 40%, depending on factors like age and aetiology. 3, 4 There is emerging evidence that among epileptic disorders status epilepticus (SE) is associated with prolonged intensive care treatment and high indirect costs because of its unfavourable outcome with premature death or loss of productivity. Furthermore, it is unknown if the introduction of newer anti-epileptic drugs causes an increase in direct costs or might be even costeffective in preventing prolonged hospital admissions.
Cost of illness (COI) studies estimate the costs which are attributed to a particular disorder and therefore may provide essential information on the burden of a disease to individuals and society. 1 The purpose of this article is to gather comprehensive information on the currently available data on the costs incurred due to SE.
Methods

Selection of studies
To identify studies that evaluated the costs of status epilepticus, a systematic literature search in electronic databases was performed, using a combined search strategy including the following keywords: cost(s), status epilepticus, cost of illness, The objective of this review is to give an overview of published cost of illness (COI) studies on status epilepticus (SE).
For identifying COI studies that evaluated the direct and indirect costs of SE, a systematic literature review was performed. We used a standardized assessment form for extracting information on the study design, methodological framework, and data sources from each publication. The results were systematically reported.
We identified only two studies worldwide, which included prevalence-or incidence-based data on the direct costs of SE: one from Germany and one from the USA. Both used a bottom-up approach and a prospective design. The estimated mean inpatient costs summed up to US$18,834 in the USA and to s8347 in Germany per admission with an average length of stay of 12.9 and 14.0 days. The mean annual direct costs for SE had been estimated at US$4 billion in the USA and at s83 million (adults only) in Germany. Both available studies indicate that SE is a cost-intensive disorder with an acute CNS aetiology as a cost-driving factor.
In conclusion, there is a paucity of data on the costs of SE. Further studies are warranted to determine costs, its predictors, quality of life, mortality data due to SE and its sequelae and to provide a basis for further cost-effectiveness calculations for new drugs and other interventions in SE and prolonged seizures.
ß cost-effectiveness, seizure. A database search was performed on MedLine, Cochrane's database of systematic reviews and HTA (Health Technology Assessment) of the UK NHS Centre for Reviews and Dissemination. We examined the reference lists of all identified studies for additional studies and asked clinical experts for additional published studies. It was assumed that this review should give a broad overview of the COI of SE, all studies which analyzed direct and/or indirect costs were considered, along with prevalence-and incidencebased studies, as well as bottom-up, top-down and modelling approaches to the COI.
Search results
A total of 65 abstracts were identified and reviewed in detail. The majority was immediately discarded because of the lack of any data on costs or the unavailable correlation between costs and status epilepticus. Finally 14 studies were selected and were retrieved in full text for subsequent revision. Only two studies included prevalence-or incidence-based data on the costs of status epilepticus and could be included in this review. These studies evaluated the costs of epilepsy/status epilepticus in Germany 5, 6 and in the USA. 7 Both studies used a bottom-up approach and applied a prospective design. Table 1 shows the results of both included studies' evaluating costs of status epilepticus. Penberthy and colleagues reported on a prospective cohort from the USA evaluated in 1993/1994 at one centre in Virginia. 7 Strzelczyk et al. described in detail a population-based cohort of adult patients with SE evaluated during a four-month period in 2008 in the German district of Marburg-Biedenkopf 5 ; the study details and analysis of epilepsy patients had been previously published. 6 
Results
Direct cost estimates
The study from the USA 7 analyzed prospectively 192 patients in all age groups and retrieved data on the direct costs for reimbursement due to inpatient admissions. The estimated mean direct costs summed up to US$18,834 per admission. The adult age group (17-45 years) were responsible for the highest amount, with median costs of US$14,689, in contrast to the paediatric age group (0-16 years), with median costs of US$6140 (Table 2) . Furthermore, increased median costs were associated with admissions due to an acute CNS aetiology (US$16,919 per adm.) in comparison to non-acute CNS aetiology with US$6669 per admission. Gender and race did not show any significant differences concerning the direct costs. The average length of stay for SE patients was 12.9 days, in comparison to other acute illness such as acute myocardial infarction with a length of stay of 7.3 days ( Table 3 ). The length of stay varied markedly and over half the patients (104/192; 54%) were admitted for less than one week. In this group the average reimbursement was approximately US$7000. For patients with over one-week's stay the figure was US$32,907. Only 10% of patients had an inpatient treatment over four weeks with resulting costs of over US$60,000 per admission The authors' projected annual direct costs for the USA due to inpatient admissions for SE were US$4 billion. The German study 5 used a population-based approach to include prospectively all adult patients with epilepsy and SE from a defined district during a four-month period. The mean direct costs per admission were calculated according to the German diagnosisrelated groups (G-DRG) and amounted to s8347. In comparison, mean inpatient costs for newly diagnosed epilepsy were s1998 and s3475 for patients with established epilepsy (Table 2) .
Inpatient treatment costs of SE due to an acute CNS aetiology were 
Indirect cost estimates
To date, no studies provide indirect costs attributed to acute treatment of SE or to sequelae caused by SE.
Discussion
There is a vast paucity of health economic data describing the costs associated with the acute treatment of SE or its long-term sequelae. We identified only two studies on COI in SE and both focused only on direct hospital admission costs due to SE.
Summarized, the direct costs for status epilepticus were higher than those for established epilepsy or newly diagnosed epilepsy. 5 In comparison to other acute health emergencies (myocardial infarction, congestive heart failure, intracranial haemorrhage) the reimbursement was 30-60% higher and underlines the high economic burden. 7 Cost-driving factors were an age group of 17-45 years and 46-64 years, as well as acute CNS aetiologies. Even multivariate analysis demonstrated age and aetiology as significant independent predictors for higher direct costs. 7 Calculating the annual direct costs associated with status epilepticus, the extrapolation for Germany amounted to s83 million for adults 5 and the extrapolation for the USA to US$4 billion for all age groups. 7 The huge difference in the extrapolation of costs between the German (approx. 80 million inhabitants) and the US (approx. 320 million inhabitants) studies can be explained by the different epidemiological assumptions of SE incidence and projection for adults only in the German study. The latter was performed in a region with a low SE incidence -between 15.8 and 17.1 per 100,000 inhabitants 4 with 11,000-12,000 affected adults per year in Germany. The US study used epidemiological data from DeLorenzo et al. 8 with a high frequency of total SE episodes at 50
per year per 100,000 population. By that they assumed 200,000 episodes of SE per year in all age groups for their projection. Either way, for the next decades the direct costs may even increase because of the demographic change and therefore increasing proportion of elderly patients. Both studies show limitations inherent to COI analysis. Using different methods of cost estimation it is difficult to compare the results. On the one hand the reimbursement used by Penberthy et al. may not reflect the costs of providing care and support, and on the other the DRG-system from the German study may not be representative of other countries. Although both studies used the traditional definition of SE (30 min), 2,3 the large diversity of the evaluation periods (1993/4 vs. 2008 ) and the number of participants may have affect the results. Both studies used different inclusion criteria: the US study 7 also included patients with hypoxia (anoxic and hypoxic insults) and alcohol withdrawal in their SE cohorts, both groups were excluded in the German study. 5 Patients with post-anoxic coma have likely a prolonged admission with high ICU costs and might be a confounder for cost differences. Furthermore, it remains difficult to draw the line between patients with post-anoxic SE and patients in coma with electrographic seizure like changes. 9, 10 Regarding treatment of SE only the German study provides details: seven out of ten patients received pre-hospital benzodiazepines and the majority (6/10) was treated with levetiracetam in hospital. During the evaluation period of the US study levetiracetam was not yet on the market and benzodiazepine use is not reported. The relatively short evaluation period of four months in the German study, a small number of SE patients (n = 10) and a restriction to one district (MarburgBiedenkopf) possibly led to a large variability of estimated costs that may not be representative for the whole of Germany or for other European countries. A major problem with COI studies in SE is differentiating between costs due to SE and costs associated with other acute illness causing the SE (e.g. acute stroke underlying the SE).
The pre-hospital treatment may also be important, given that it influences the cessation and therefore length of SE. Neither study evaluated the influence of pre-hospital treatment on inpatient costs and outcome. Established drugs for out-of-hospital treatment are diazepam, lorazepam, clonazepam and midazolam as they can be administered by laymen and paramedics using the buccal, intranasal, intravenous and rectal route. demonstrates potential cost savings due to a pre-hospital treatment of prolonged seizures, but also points towards the lack of reliable data on inpatient costs for treatment of prolonged seizures or SE.
Conclusion
Available COI studies confirm SE as a cost-intensive disorder and point towards an urgent need for more detailed and comparable COI studies. Due to demographic change, the amount of affected persons will rise and the budget impact for the treatment of SE will increase. At the moment there is a complete lack of studies on indirect costs or on cost due to sequelae caused by SE. To date, no studies have used an operational definition of persistent seizure activity for 5 min or more as signifying SE. Further studies are warranted to determine costs, its predictors, quality of life, mortality data due to SE and its sequelae and to provide a basis for further cost-effectiveness calculations for new drugs and other interventions in SE and prolonged seizures.
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